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Objective: To explore the ability of chemokines in plasma to detect the presence of pre-X-rays deﬁned
knee degeneration and the extent (burden).
Methods: A total of 181 subjects (75 control subjects, 47 pre-X-KD patients and 50 X-KOA patients) were
included and subdivided into three subgroups. Articular cartilage loss in pre-X-KD patients were scored
on the basis of the ICRS classiﬁcation during the arthroscopy or documented on MRI with chondral
WORMS. The severity of X-KOA was graded using the KellgreneLawrence classiﬁcation through the
posterioreanterior knee X-rays. The concentrations of the inﬂammatory cytokines and chemokines in
plasma were quantiﬁed using Luminex microbead-based suspension array (SA) and were cross-validated
by enzyme-linked immunosorbent assay (ELISA).
Results: CCL3 in plasma showed the highest ability to discriminate pre-X-KD patients from the controls
with an AUC of 0.799. At a cutoff value of 0.168 pg/ml, the sensitivity was 70.21%, the speciﬁcity was
96.00%, the positive predictive value was 91.67% and the negative predictive value was 83.72%. As to
deﬁne disease burden, the plasma levels of resistin, IL6, IL8, CCL3 and CCL4 showed signiﬁcant associ-
ation with the severity of X-rays deﬁned knee OA, with regard to the KL classiﬁcation. Moreover, sig-
niﬁcant elevation of IL6, IL8, CCL3 and CCL4 levels in plasma were observed in severe knee OA patients
(KL grade IV) compared with those with pre-X-KD (KL grade 0eI).
Conclusion: We ﬁrstly showed that the plasma CCL3 could be potential serum biomarker for knee OA
with the capacity to detect pre-X-rays deﬁned changes and stage the severity of damage in knee.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Osteoarthritis (OA) is the most prevalent musculoskeletal dis-
order and the major cause of functional incapacity and disability in
adults. The World Health Organization's 2010 report on global
burden of disease estimated that OA of the knee and hip has ranked
as the eleventh leading cause of years lived with disability (YLD)
and the knee accounted for 83% of the burden1. In the past decade
increasing lines of evidence have demonstrated that OA not only
disorder the affected joint, but also the general physical function.to: Z. Zhang and W. Liao,
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ternational. Published by Elsevier LMany studies have showed that patients with OA are at signiﬁcantly
higher risk of developing comorbid conditions than people without
this disease2. Moreover, patients with knee or hip OAwere found to
have higher all-cause mortality rates than general populations3,4.
At present, the diagnosis of OA are mostly based on symptom-
atic and X-ray indicators, such as pain, stiff of joint, osteophytes and
joint space narrowing5. However, OA changes such as articular
cartilage abnormalities are slow and insidious in symptomatic and
X-ray indicators, and thus often unrecognized until irremediable
joint damage has occurred. In other words, currently established
means can no longer satisfy the diagnosis and treatment of OA, so
does the development of disease modifying OA drug (DMOAD).
Therefore, a new tool that can facilitate earlier diagnosis of OA,
monitor disease progression is urgently needed and, most impor-
tantly, it should be simple and practicable which is easily
popularized.td. All rights reserved.
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surrogate to reﬂect the current status of OA. Biomarker is a group of
genetic and biochemical molecules that associated with the
development of speciﬁc disease. For a successful OA biomarker, it
must be able to loyally measure and predict the full spectrum of OA
progression and outcomes6. Identiﬁcation of candidate novel bio-
markers in OA has become one of the study hotspots in recent
years. Several plasma biomarkers have been identiﬁed in OA, such
as keratan sulfate7, pentosidine8, and cartilage oligomericmatrix
protein (COMP)9, which tend to be increased in OA patients.
Inﬂammation is now widely accepted to be an essential part of
OA, chemokines as mediators of chemoattraction (chemotaxis) are
known to play a vital role in this process10e12. Chemokines have
similar protein structures being 6e14 kDa, with two major sub-
classes having conserved cysteine residues either adjacent (CC) or
separated by one amino acid (CXC)12. We have shown that a large
set of chemokine genes, especially CCL3, CCL4, CXCL1 and CXCL8
(IL8), is up-regulated by the pro-inﬂammatory cytokine interleukin
1b (IL1b) and resistin in chondrocytes, from either adult normal
cartilage or patients with OA13,14. It can be expected that the in-
crease in a wide range of chemokines will have a signiﬁcant impact
on the cells of cartilage and other related joint tissues, and should
be considered in the pathophysiology of OA. However, their kinetics
in plasma as OA biomarker was rarely reported.
In present study, we investigated the plasma levels of CCL3,
CCL4, CXCL1 and CXCL8 (IL8) and the common proinﬂammatory
indicators, such as IL1b, IL6, tumor necrosis factor alpha (TNFa)15
and resistin16, in healthy adults and patients with different stages
of knee OA and tended to explore the ability of chemokines in
plasma to detect the presence of pre-X-rays deﬁned knee degen-
eration and the extent (burden).
Materials and methods
Patients. This study was approved by the Institutional Review
Board of Sun Yat-sen University and was conducted in accordance
with the Helsinki Declaration (IRB No. 2011-11). Patients diagnosed
with or without knee OA between September 1, 2012 and December
31, 2013 inourhospitalwereconsidered forour study.Demographics,
comorbidities, medications and the history of knees affected were
prospectively collected. Written informed consent was obtained
from all patients prior to their participation in this study.
Grading of knee OA. The standard anteroposterior and lateral
weight-bearing X-rays of both knees were taken routinely after
admission. Pre-operative knee ﬁlms were evaluated with the
KellgreneLawrence (KL) grading scale in a blinded fashion by two
orthopaedic surgeons and one radiologist. Atlas published by
R Altman17 was used during X-rays reading. When discrepancies
were noted, a grade was assigned after consensus had been
reached. For ethical reasons, no other joints were radiographed, if
patients did not report pain.
The patients, who suffered pain but did not have evidence of
knee OA as assessed by X-rays, were suggested to have further knee
examination by magnetic resonance imaging (MRI) or arthroscopy.
MRI was acquired with a 3.0 T imaging system (Siemens Medical
Solutions, Erlangen, Germany) and T1WI, T2WI and fat-suppressed
sequences were routinely acquired. MRIs of tibiofemoral joint
cartilage were graded using the Whole-Organ MRI Score (WORMS)
with an eight-point scale from 0 (normal) to 6 (most severe carti-
lage erosion). All MRIs were scored by above three readers who
were blinded to the patient. Arthroscopy, if necessary, was per-
formed using a 30 angled arthroscope (Smith & Nephew, Andover,
Massachusetts, USA). The arthroscopic evaluation was carried out
by two trained arthroscopists according to the International Carti-
lage Repair Society (ICRS) grading system.Inclusion and exclusion criteria of patients. Control subjects
were recruited from patients admitted for cosmetic surgery during
this period in our hospital. Individuals who free of exposure to
potential risk factors of OA were enrolled. None of the control
subjects had evidence of OA assessed by clinical examination,
questionnaire and X-ray ﬁlms.
The knee OA patients included in present studywere subdivided
into pre-X-rays deﬁned knee degeneration (pre-X-KD) group or X-
rays deﬁned knee OA (X-KOA) group. Pre-X-KD patients18 were
those suffered pain at least two episodes for more than 10 days in
the last year with the history of meniscus or knee ligament injuries
and the preoperative X-rays did not show obvious OA sign (KL
grade 0eI). But cartilage degeneration was documented on pre-
operative MRI with chondral WORMS 3e6 or by arthroscopic
assessment with ICRS grade IIeIV in one compartment with sur-
rounding softening and swelling or grade IeIV in at least two
compartments. X-KOAwas deﬁned as at least one knee met clinical
ACR criteria with KL grade IIeIV.
The proportion of patients excluded under each criterion was as
follows: patients with any other form of knee arthritis, like rheu-
matoid arthritis (RA) and infectional arthritis; those underwent
knee arthroplasty or suffered knee injury in 3 months; a recent
history (within 3 months) of an intra-articular injection or received
non-steroidal anti-inﬂammatory drugs in last week; a prior history
of clinically evidenced OA in any other joint; autoimmune disease;
obesity (BMI > 30); patients who presented signs of acute or
chronic inﬂammatory disease; exposure to any disease or treat-
ment known to inﬂuence bone metabolism, such as diabetes mel-
litus, hyperthyroidism and hyperparathyroidism; patients with
incomplete clinical or laboratory data.
Plasma samples collection and biomarkers measurement.
Following a 12 h overnight fast, venous blood samples were
collected from all subjects into ethylene diamine tetraacetic acid
(EDTA)-containing Vacutainer tubes. Samples were maintained at
4C within 1 h of collection until processed. After separation of
plasma by centrifugation (15 min, 1000g), the plasma was divided
into aliquots and stored at 80C until analyzed. All plasma sam-
ples were obtained prior to any treatment and were measured in 3
months.
The concentrations of eight inﬂammatory cytokines and che-
mokines (IL1b, IL6, TNFa, resistin, CCL3, CCL4, CXCL1 and IL8) were
quantiﬁed in plasma samples (50 mL) of all subjects using the
Luminex microbead-based suspension array (SA) (Procarta, Affy-
metrix, California, USA), following the manufacturer's protocol in a
96 well plate format. After that, the assayed samples were analyzed
by Bio-Plex 200 system (Bio-Rad, Hercules, California, USA)
immediately. Although the Luminex multianalyte assay has been
validated previously against standard enzyme-linked immunosor-
bent assay (ELISA) tests with use of human blood samples19,20, we
performed another cross-validation experiment for 2 chemokines
(CCL3 and CCL4). On the other hand, 42 samples from 5 control
participants, 18 pre-X-KD and 19 X-KOA patients were determined
using human CCL3 and CCL4 ELISA kits (eBioscience, Affymetrix,
California, USA) according to the manufacturer's instructions.
Statistical analysis. Statistical analysis was performed using
SPSS v13.0 statistical software (SPSS Inc., Chicago, IL, USA).
Continuous variables were expressed as the mean with standard
deviation or 95% conﬁdence interval. Univariate ANOVA analysis
and LSD test or Tamhane's T2 test were used to compare the means
of more than two independent groups. If the values were not
normally distributed, log transformation was performed to obtain
approximately normal distributions or be compared using Wil-
coxon rank sum scores, which do not depend on distributions.
Categorical variables were expressed as frequency and were
analyzed with Chi-squared test and Fisher's exact test. Correlation
Table I
Clinical characteristics of knee degenerative (OA) patients and controls
X-KOA patients (n ¼ 50) pre-X-KD patients (n ¼ 47) Controls (n ¼ 75)
Age (years) 61.30 ± 13.63*# 29.02 ± 8.59* 43.23 ± 10.98
Gender (F/M) 36/14# 20/27 47/28
BMI (kg/m2) 24.61 ± 2.46# 22.90 ± 2.03* 24.50 ± 2.47
OA knees (bilateral/unilateral) 47/3 0/47 0/0
Radiographic KL gradey
KL grade 0 0 25 75
KL grade I 0 22 0
KL grade II 11 0 0
KL grade III 13 0 0
KL grade IV 26 0 0
Data were described as mean ± standard deviation or number.
*For P < 0.0 5 vs controls; #For P < 0.05 vs pre-X-KOA patients.
KL, Kellgren and Lawrence grading scale; X-KOA, X-rays deﬁned knee osteoarthritis; pre-X-KD, pre-X-rays deﬁned knee degeneration.
y For patients who had bilateral OA, KL grade from the worse knee was used.
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correlation coefﬁcient. Correlation between ordinal categorical
variables and quantitative variables was analyzed using Spearmen's
correlation coefﬁcient. A P-value of <0.05 was considered statisti-
cally signiﬁcant.
Receiver operating characteristic (ROC) curves were calculated
for evaluation of predictive ability of the studied cyto-chemokines.
The area under the ROC curve (AUC) was the measure of howwell a
parameter can distinguish between two diagnostic groups (pre-X-
KD and control). The optimal cutoff value was obtained from You-
den index which has the maximum sum of speciﬁcity and sensi-
tivity. Furthermore, the effectiveness of a biomarker to predict pre-
X-rays deﬁned knee degeneration was calculated through sensi-
tivity, speciﬁcity and predictive values.
Results
The baseline characteristics of study subjects. A total of 622
people (284 control subjects and 338 knee OA patients) partici-
pated in present study. Finally,181 participants (75 control subjects,
47 pre-X-KD patients and 50 X-KOA patients) were included and
subdivided into three subgroups according to the presence of
clinical and imaging data. The clinical characteristics of all patients
were presented in Table I. pre-X-KD patients tended to be signiﬁ-
cantly younger (F ¼ 74.51, P < 0.001), more predominantly male
(c2 ¼ 9.17, P ¼ 0.01), and have lower BMI (F ¼ 8.32, P < 0.001)
compared with the control, while patients with X-KOA were just
the opposite. Of these knee degenerative patients, 47 pre-X-KD
patients were all unilateral and the X-KOA patients were 3 unilat-
eral and 47 bilateral.
For the eight cyto-chemokines, the levels of plasma resistin
(Tamhane's T2 test, P ¼ 0.019), IL8 (Tamhane's T2 test, P ¼ 0.044)
and CCL3 (Tamhane's T2 test, P < 0.001) were signiﬁcantly elevated
from the control to the pre-X-KD patients. Meanwhile, X-KOA pa-
tients showed signiﬁcantly higher IL6 (Tamhane's T2 test,
P ¼ 0.014), IL8 (Tamhane's T2 test, P < 0.001), CCL3 (Tamhane's T2
test, P < 0.001) and CCL4 (Tamhane's T2 test, P ¼ 0.005) levels
compared with those with pre-X-KD. But no signiﬁcant differences
were found in plasma level of IL1b (F ¼ 0.27, P ¼ 0.768), TNFa
(F ¼ 0.66, P ¼ 0.52) and CXCL1 (F ¼ 0.93, P ¼ 0.40) among three
groups (Table II). In addition, the plasma levels of these cyto-
chemokines also demonstrated a positive correlation with each
other (r value ranged from 0.15 to 0.59, P < 0.05). A signiﬁcant
positive correlation was detected between CCL3 and other cyto-
chemokines, including CCL4, resistin, IL6 and IL8(r ¼ 0.42, 0.38,
0.26, 0.57, P < 0.001 for CCL4, resistin, IL6 and IL8).
As known, BMI, gender, and age were not equally distributed
among the three groups, therefore, we assessed the inﬂuences ofthem on levels of cyto-chemokines in plasma through statistical
analysis in controls. As shown in Fig. 1, all cyto-chemokines were
independent of age, BMI and gender except for TNFa and IL6, which
showed a signiﬁcant positive correlation with age(r ¼ 0.30,
P ¼ 0.006 and r ¼ 0.38, P ¼ 0.001, for TNFa and IL6, respectively).
The ability of cyto-chemokines in plasma to diagnose pre-X-
rays deﬁned knee degeneration. The ability of plasma cyto-
chemokines to discriminate pre-X-KD patients from control sub-
jects was evaluated using ROC curve analysis (Fig. 2). The highest
AUCwas found for CCL3, followed in order by IL8, resistin, IL6, CCL4,
IL1b, TNFa and CXCL1. The AUC for CCL3 is 0.799 and the optimal
cutoff value for CCL3 is 0.168 pg /ml, at which plasma CCL3 can
detect pre-X-KD patients at 70.21% of sensitivity, 96.00% of speci-
ﬁcity, 91.67% of positive predictive value and 83.72% of negative
predictive value.
The ability of cyto-chemokines in plasma to stage the burden
of knee OA. With regard to the radiological KL classiﬁcation, the 97
knee OA patients, including 47 pre-X-KD patients and 50 X-KOA
patients, were classiﬁed into four groups. 47 patients were cate-
gorized as grade 0-I, 11 as grade II, 13 as grade III and 26 as grade IV.
When the patients were affected in both knees, the grading of the
worst affected knee was used for analysis. Spearmen correlation
analysis showed that resistin (r ¼ 0.25, P ¼ 0.015), IL6 (r ¼ 0.36,
P < 0.001), IL8 (r ¼ 0.34, P ¼ 0.001), CCL3 (r ¼ 0.68, P < 0.001) and
CCL4 (r ¼ 0.48, P < 0.001) levels in plasma were positively corre-
lated with KL grades. As demonstrated in Fig. 3, IL6 (F ¼ 4.08,
P¼ 0.009), IL8 (F ¼ 5.27, P ¼ 0.002), CCL3 (F ¼ 25.80, P < 0.001) and
CCL4 (F ¼ 9.23, P < 0.001) were signiﬁcantly elevated from knee OA
patients with KL grade 0eI/II to those with KL grade III/IV. But there
was no signiﬁcant difference in the plasma resistin (F ¼ 1.99,
P ¼ 0.12) level among patients with different KL grades.
ELISA cross-validation for plasma CCL3 and CCL4. We chose
ELISA for comparison with the Luminex microbead-based
SA because the ELISA is a generally accepted method for
analyzing biomarkers in human plasma. According to current data,
expression levels of ELISA and SA were signiﬁcantly different
(P < 0.001). The concentration of CCL3 determined by ELISAwas, on
the average, 10-fold greater than that determined by the SA, and
CCL4 determined by ELISAwas six-fold lower than that determined
by the SA. However, relative to each other, the two assays were
signiﬁcantly correlated (P < 0.001) and the correlation coefﬁcients
(r) were 0.83 and 0.79 for CCL3 and CCL4, respectively (Fig. 4).
Discussion
Being able to provide diagnosis of OA at an early stage or
monitor disease progression timely will greatly develop early
treatment of OA as a strategy to prevent or delay the onset of classic
Table II
Plasma levels of cyto-chemokines in knee OA patients and controls
X-KOA patients (n ¼ 50) pre-X-KD patients (n ¼ 47) Controls (n ¼ 75)
IL1b (pg/ml) 1.42 (1.28e1.55) 1.33 (1.20e1.45) 1.34 (1.24e1.44)
IL6 (pg/ml) 6.46 (5.86e7.05)*# 5.52 (5.26e5.78) 5.38 (5.12e5.63)
TNFa (pg/ml) 10.23 (9.16e11.29) 9.89 (9.12e10.67) 10.71 (10.02e11.41)
Resistin (pg/ml) 1069.08 (943.90e1194.26)* 892.98 (777.13e1008.83)* 710.73 (651.75e769.71)
CXCL1 (pg/ml) 5.63 (4.49e6.78) 5.41 (4.50e6.32) 5.85 (5.37e6.32)
IL8 (pg/ml) 1.84 (1.66e2.02)*# 1.23 (1.09e1.38)* 1.02 (0.94e1.11)
CLL3 (pg/ml) 1.86 (1.58e2.14)*# 0.57 (0.41e0.72)* 0.06 (0.04e0.09)
CCL4 (pg/ml) 598.70 (518.68e678.71)*# 435.27 (374.41e496.12) 417.50 (371.79e463.21)
Data were described as mean (95% conﬁdence interval). *For P < 0.05 vs controls; #For P < 0.05 vs pre-X-KD patients. X-KOA, X-rays deﬁned knee osteoarthritis; pre-X-KD,
pre-X-rays deﬁned knee degeneration.
Fig. 1. Correlation analyses of the levels of cyto-chemokines in plasma compared with age (A) and BMI (B) in control subjects. Scattergrams showing that TNFa and IL6 in plasmawas
signiﬁcantly positively correlated with age (r ¼ 0.30, P ¼ 0.006 and r ¼ 0.38, P ¼ 0.001). The other cyto-chemokines were independent of age and BMI. BMI, body mass index.
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regulated by the pro-inﬂammatory cytokine IL1b and resistin in
chondrocytes13,14. In this study, we investigated the plasma levels
of CCL3, CCL4, CXCL1, CXCL8 (IL8), IL1b, IL6, TNFa and resistin, in
control subjects without OA, patients in the pre-X-KD stage and
those with X-KOA. According to the assessment by ROC curves,
CCL3 was suggested to be the most potential diagnostic biomarker
to discriminate pre-X-KD patients from controls. Meanwhile,
comparison among OA patients with different KL grades indicated
that CCL3, CCL4, IL6 and IL8 in plasma were signiﬁcantly associatedwith the severity of X-rays deﬁned knee OA. When considering the
inﬂuence of BMI, age and gender, TNFa and IL6 are not the reliable
indexes as a biomarker.
It was unexpected that IL-1b and TNFa, both traditionally noted
as major contributors to cartilage matrix degradation in OA, were
not signiﬁcantly elevated in serum of either pre-X-KD or X-KOA
patients in this study. The involvement of IL8 and resistin in the
pathogenesis of OA are supported by the observation that intra-
articular injection of either IL8 or resistin can initiate arthritis in
healthy animal joints21,22. Moreover, their important role in
Fig. 2. ROC curves for studied cytochemokines that discriminate pre-X-KD patients
from the controls. The highest AUC was found for CCL3, followed in order by IL8,
resistin, IL6, CCL4, IL1b, TNFa and CXCL1. The AUC for CCL3 is 0.799 and the optimal
cutoff value for CCL3 is 0.168 pg/ml. ROC curves, receiver operating characteristic
curves; AUC, area under the ROC curve; pre-X-KD, pre-X-rays deﬁned knee
degeneration.
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products, mononuclear cell chemotaxis, proteoglycan synthesis
inhibition, chondrocyte apoptosis were demonstrated in vitro.
Parallelly, in OA patients, IL8 and resistin were presented in high
quantities in serum, synovial ﬂuid and tissue, which was in
agreement with our data. These data suggest that IL8 and resistin in
plasma can partly reﬂect the progression of OA, albeit were not as
outstanding as CCL3.Fig. 3. Comparison of plasma cyto-chemokines levels in patients with knee OA classiﬁed ac
P ¼ 0.002), CCL3 (F ¼ 25.80, P < 0.001) and CCL4 (F ¼ 9.23, P < 0.001) showed signiﬁcant elev
were diagrammed as mean and 95% conﬁdence interval. KL, Kellgren and Lawrence gradinSigniﬁcant increasing of CCL4 in synovial tissue of OA patients
has been demonstrated by immunohistochemistry evaluation23.
Our previous studies also noted high expression of CCL4 in human
articular chondrocytes treated with resistin14. The present study
showed that the CCL4 level in plasma was signiﬁcantly elevated in
severe knee OA patients (KL grade IV) compared with those with
pre-X-KD (KL grade 0eI). The CCL4 level in the plasma was posi-
tively correlated with the severity of knee OA, even though the
differences among patients with pre-X-KD, KL grade II and KL grade
III were not signiﬁcant. Interestingly, CCL4, not like most of cyto-
chemokines that appeared to be expressed at greater levels in RA
than in other forms of inﬂammatory arthritis, was found signiﬁ-
cantly higher in the synovial ﬂuid obtained from OA patients
compared to RA ones23.
CCL3 and CCL4 are highly related members of the CC chemo-
kines family, encoded by genes located on chromosome 17. Despite
their structural similarities, CCL3 and CCL4 showed diverging
signaling capacities24. Study in human nucleus pulposus cells
showed that CCL3, but not CCL4, played a role in promoting
macrophage migration and local tissue degeneration25. Generally,
CCL3 is not synthesized and released in resting cells. But, upon
stimulation with one of several proinﬂammatory agents/cyto-
chemokines, large amounts of CCL3 could be produced by T-lym-
phocytes, neutrophils, macrophage and some special non-immune
cells24. This is consistent with our ﬁndings that, in plasma of control
subjects, only low level of CCL3 were detected. But a signiﬁcant
secretion of CCL3 in plasmawas observed in pre-X-KD patients and
it was continuous elevated in X-KOA patients. The dramatic
increasing of CCL3 in plasma, in other hand, denoted its important
status in inﬂammation associated with OA. Studies in RA26 also
suggested that CCL3 was critical for the selective recruitment of
circulating monocytes. H€ansch et al. moreover, pointed that CCL3
induced the differentiation of monocytes to osteoclasts, which wascording to Kellgren and Lawrence grading scale. IL6 (F ¼ 4.08, P ¼ 0.009), IL8 (F ¼ 5.27,
ation from knee OA patients with KL grade 0eI or II to those with KL grade III or IV. Data
g scale; OA, osteoarthritis.
Fig. 4. ELISA cross-validation for plasma CCL3 and CCL4 in 42 samples. The concentration of CCL3 and CCL4 in plasma determined by ELISA were signiﬁcantly positively correlated
with that determined by SA (r ¼ 0.83, P < 0.001 and r ¼ 0.79, P < 0.001for CCL3 and CCL4, respectively). SA, Luminex microbead-based suspension array.
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kataraman et al.28 using MIP-1a / mice directly demonstrated
the essential role of CCL3 in the development of joint arthritis. Its
ability to inhibit osteoblast function may also contribute to the
development of OA29,30.
Experiments in guinea pig have proved signiﬁcant correlation
between serum level of CCL3 and the severity of histological
damage of OA31. In our study, CCL3 in plasma showed the best
diagnostic potency with high levels of speciﬁcity and positive
predictive value for pre-X-KD. It means, in subjects with predom-
inantly normal ﬁndings on X-ray if their plasma CCL3 level is pos-
itive, there is a great possibility of them having been suffering from
pre-X-KD and the misdiagnosis rate is low. As to deﬁne disease
burden, knee OA patients with KL grade III/IV showed signiﬁcantly
elevated CCL3 level in plasma compared with those with KL grade
0eI and II. This is consistent with the ﬁndings from knee synovial
ﬂuid32.
What is more, we found that plasma level of CCL3 was tightly
related to other cyto-chemokines, including CCL4, resistin, IL6 and
IL8. The strong positive correlation among above in OA may results
from the signals, mechanisms and functions of them. Chomarat
et al.33 reported that IL6 was essential to switch monocyte differ-
entiation to macrophages, which was regarded as an important
source of CCL3 and CCL4 in OA. Greatly decreasing of the IL1b-
induced IL6 and IL8 was noted by blocking p38 and ERK1/2 MAPK
signaling pathway34. Our previous study also demonstrated the
important regulatory role of C/EBPb and NFkB in CCL3 and CCL4
expression in human chondrocyte in response to IL1b and resis-
tin35,36. These data, in proﬁle, revealed the importance of CCL3 and
CCL4 during OA pathogenesis.
However, there are several limitations to this study. First, the
study was performed on a relatively small sample and, therefore, it
was difﬁcult to balance the confounding factors, like age, gender,
and BMI between pre-X-KD group and X-KOA group. Second, the
incidence of knee OA and risk factors distribution were quite
different from those in reality. Thus, the optimal cutoff value for
CCL3, calculated by ROC curve analysis, can only be used in this
study, aiming to achieve speciﬁc objectives. The third was that the
pre-X-KD patients, recruited in our study, were all suffered from
pain or some functional limitation but those without obvious
symptomswere absent. Additionally, our study did not examine the
effect of OA comorbidity in the other joints, which needmuchmore
radiographic data and beyond the scope of present study.
In summary, we have ﬁrstly identiﬁed a signiﬁcantly increase of
the CCL3 level in plasma from the control subjects to the pre-X-KD
patients. As only a small volume of blood is required, CCL3 may
further be used as a diagnostic tool to screening people with highrisk of knee OA. Moreover, CCL3 and CCL4 have been currently
demonstrated to be correlated with the severity of knee OA. Aside
from the traditional radiological method (X-ray), the CCL3 and CCL4
levels in plasma may serve as potential burden-of-disease bio-
markers to stage the severity of knee OA. Of course, these ﬁndings
should be validated by further large sample clinical studies. In our
further studies, we will focus on the association of CCL3 in plasma
with the pre-X-rays deﬁned degenerative changes, such as the MRI
scoring and arthroscopy grades. Furthermore the mechanisms of
CCL3 participate in bone-cartilage damages in OA development
need further investigation.
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